Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement
Open accessThe DOI matches its Crossref record; 102 of the 106 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Genome sequencing and gene-based therapies appear poised to advance the management of rare lipoprotein disorders and associated dyslipidaemias. However, in practice, underdiagnosis and undertreatment of these disorders are common, in large part due to interindividual variability in the genetic causes and phenotypic presentation of these conditions. To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. The task force also recognises the scarcity of quality information regarding the prevalence and outcomes of these conditions. Collaborative registries are needed to improve health policy for the care of patients with rare dyslipidaemias.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Homozygotes for the receptor defective ε2 allele have the propensity to develop the highly atherogenic dysbetalipoproteinemia with high levels of both total cholesterol and triglycerides [7,14]”
From APOE and vascular disease: Sequencing and genotyping in general population cohorts (2023) · cites this paper as [14]
In the citing paper
“Mutations in the LDL receptor–binding domain, as the APOE Arg154Ser Christchurch, as well as the presently identified Gly145Asp and Arg154Cys mutations, are also associated with dysbetalipoproteinemia—a condition that is, however, treatable with standard lipid medications. 32”
From APOE and dementia – resequencing and genotyping in 105,597 individuals (2020) · cites this paper as [32]
In the citing paper
“However, accumulating evidence indicates greater complexity, involving apoAV, ANGPTL3, 4 and 8, lipase maturation factor-1 (LMF1), and glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein (GPIHBP1)18,56 (Figure 4).”
Citations
Cites
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationNordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Self-citationCuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationHamel, C. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-40 · Cited by 962
Cholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport
Rosenson, R. S., Brewer, H. B., Davidson, W. S., Fayad, Z. A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X.-C., Phillips, M. C., Rader, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.066589 · Cited by 953
Self-citationInazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., & Tall, A. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231803 · Cited by 861
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Madsen, C. M., Varbo, A., & Nordestgaard, B. G. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx163 · Cited by 715
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 632
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“Complete loss-of-function (LOF) mutations in genes encoding several of these proteins can cause severe hypertriglyceridaemia (LpL, apoCII, apoAV, LMF1, and GPIHBP1) or hypolipidaemia (apoCIII, ANGPTL3, and ANGPTL4).”
BackgroundInfluentialSelf-citationA Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 469
“A detailed discussion is beyond the scope here; the interested reader is referred to a recent review (128).”
BackgroundSelf-citationCuchel, M., Raal, F. J., Hegele, R. A., Al-Rasadi, K., Arca, M., Averna, M., Bruckert, E., Freiberger, T., Gaudet, D., Harada-Shiba, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad197 · Cited by 359
“cholesterol ester storage disease), caused by bi-allelic pathogenic variants in the LIPA gene, and for which enzyme replacement treatment is available.(18) Patients with cerebrotendinous xanthomatosis may have xanthomas resembling HoFH but plasma cholesterol levels are normal to mildly elevated (with elevated cholesta…”
BackgroundInfluentialSelf-citationManaging Atherosclerotic Cardiovascular Risk in Young Adults
Stone, N. J., Smith, S. C., Orringer, C. E., Rigotti, N. A., Navar, A. M., Khan, S. S., Jones, D. W., Goldberg, R., Mora, S., Blaha, M., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.016 · Cited by 233
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study
Tromp, T. R., Hartgers, M. L., Hovingh, G. K., Vallejo-Vaz, A. J., Ray, K. K., Soran, H., Freiberger, T., Bertolini, S., Harada-Shiba, M., Blom, D. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02001-8 · Cited by 205
Self-citation
Metadata
- Authors
- Hegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., Frikke-Schmidt, R., Gaudet, D., Hovingh, G. K., Kronenberg, F., Lütjohann, D., Parhofer, K. G., Raal, F. J., Ray, K. K., Remaley, A. T., Stock, J. K., Stroes, E. S., Tokgözoğlu, L., & Catapano, A. L.
- Affiliations
- Western University (CA)
- Sahlgrenska University Hospital (SE)
- Columbia University (US)
- Sapienza University of Rome (IT)
- University of Palermo (IT)
- Medical University of Vienna (AT)
- University of Milan (IT)
- Inserm (FR)
- University of Pennsylvania (US)
- Hôpital de Chicoutimi (CA)
- Amsterdam UMC Location University of Amsterdam (NL)
- Innsbruck Medical University (AT)
- University Hospital Bonn (DE)
- Ludwig-Maximilians-Universität München (DE)
- University of the Witwatersrand (ZA)
- Imperial College London (GB)
- National Institutes of Health (US)
- European Atherosclerosis Society (SE)
- Hacettepe University (TR)
- Corresponding author
- Hegele, Robert A
- ORCID
- Hegele, Robert A
- Borén, Jan
- Ginsberg, Henry N
- Arca, Marcello
- Averna, Maurizio
- Binder, Christoph J
- Calabresi, Laura
- Chapman, M John
- Cuchel, Marina
- Gaudet, Daniel
- Hovingh, G Kees
- Kronenberg, Florian
- Lütjohann, Dieter
- Parhofer, Klaus G
- Raal, Frederick J
- Ray, Kausik K
- Remaley, Alan T
- Stroes, Erik S
- Tokgözoğlu, Lale
- Catapano, Alberico L
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 8
- Issue
- 1
- Pages
- 50-67
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2978430228
- Cited by
- 204
- References
- 106
- Citations by year
- 2026: 33 · 2025: 27 · 2024: 35 · 2023: 30 · 2022: 29 · 2021: 27 · 2020: 20
- FWCI
- 18.87
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- Boehringer Ingelheim
- MedImmune
- Amgen
- Janssen Pharmaceuticals
- Institut de Cardiologie de Montréal
- Eli Lilly and Company
- Regeneron Pharmaceuticals
- HLS Therapeutics
- Pfizer
- REGENXBIO
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Unilever
- Novo Nordisk
- Merck
- European Atherosclerosis Society
- Novartis
- European Commission
- Sanofi
- Daiichi-Sankyo
- Meso Scale Diagnostics
- Akebia Therapeutics
- Ionis Pharmaceuticals
- Silence Therapeutics
- GlaxoSmithKline
- Medicines Company
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- lipoprotein metabolism disorders, LDL cholesterol, triglycerides, HDL cholesterol, genotype-phenotype variability, underdiagnosis, undertreatment, gene therapy, genome sequencing, clinical management, patient registry, health policy
- MeSH terms
- Europe, Genotype, Humans, Phenotype, Practice Guidelines as Topic, Disease Management, Genetic Predisposition to Disease, Consensus, Rare Diseases, Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30264-5
- The paper
- Hegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., Frikke-Schmidt, R., Gaudet, D., Hovingh, G. K., Kronenberg, F., Lütjohann, D., Parhofer, K. G., Raal, F. J., Ray, K. K., Remaley, A. T., . . . Catapano, A. L. (2020). Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30264-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.